Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Исследование селторексанта по сравнению с кветиапином XR в качестве дополнительной терапии к антидепрессантам у взрослых и пожилых участников с большим депрессивным расстройством с симптомами бессонницы, которые неадекватно реагировали на терапию антидепрессантами

11 ноября 2026 г. обновлено: Janssen Research & Development, LLC

Двойное слепое рандомизированное исследование в параллельных группах с использованием кветиапина пролонгированного высвобождения в качестве препарата сравнения для оценки эффективности и безопасности селторексанта 20 мг в качестве дополнительной терапии к антидепрессантам у взрослых и пожилых пациентов с тяжелым депрессивным расстройством с симптомами бессонницы, которые неадекватно реагировали на терапию антидепрессантами.

The purpose of this study is to assess the efficacy of seltorexant compared with quetiapine extended-release (XR) as adjunctive therapy to an antidepressant drug in treatment response in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).

Обзор исследования

Подробное описание

Major depressive disorder (MDD) is a common, serious, recurrent disorder. Seltorexant (JNJ-42847922) is a potent and selective antagonist of the human orexin-2 receptor (OX2R) that is being developed for the adjunctive treatment of MDDIS. The hypothesis for this study is that seltorexant is superior to quetiapine XR in leading to a response after 26 weeks of treatment (greater than or equal to [>=] 50 percent [%] improvement on baseline Montgomery Asberg Depression Rating Scale [MADRS] total score), when administered as adjunctive treatment to an antidepressant in adult and elderly participants with MDDIS who have had an inadequate response to treatment with an SSRI/SNRI. The study will be conducted in 3 phases: a screening phase (up to 30 days), a double-blind (DB) treatment phase (26 weeks), and a post treatment follow-up phase (7 to 14 days after the end of DB treatment phase for all participants, and up to 196 days from baseline for participants who stop study treatment early). The total study duration for each participant will be approximately 32 weeks. Efficacy, safety, pharmacokinetics, and biomarkers will be assessed at specified time points during this study.

Тип исследования

Интервенционный

Регистрация (Действительный)

757

Фаза

  • Фаза 3

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Места учебы

      • Buenos Aires, Аргентина, 1058AAJ
        • CENydET - Centro Neurobiologico y de Stress Traumatico
      • Buenos Aires, Аргентина, C1405BOA
        • FunDaMos
      • Buenos Aires, Аргентина, 1199
        • Hospital Italiano
      • Ciudad Autonoma Buenos Aires, Аргентина, C1428AQK
        • Hospital Fleni
      • Córdoba, Аргентина, X5004AOA
        • Instituto Privado Kremer
      • Córdoba, Аргентина, 5000
        • Fundacion Lennox
      • Córdoba, Аргентина, X5006IKK
        • Centro Medico Luquez
      • La Plata, Аргентина, Thanks
        • Clinica Privada de Salud Mental Santa Teresa de Ávila
      • La Plata, Аргентина, 1902
        • CENPIA
      • Mendoza, Аргентина, M5502AWY
        • CENAIN
      • San Miguel de Tucumán, Аргентина, 4000
        • Clinica Mayo de UMCB
      • Bruges, Бельгия, 8310
        • AZ Sint-Lucas
      • Sint-Niklaas, Бельгия, 9100
        • AZ Nikolaas
      • Pleven, Болгария, 5800
        • Medical Center Medconsult-Pleven
      • Plovdiv, Болгария, 4028
        • MC 'Hipokrat - N', EOOD
      • Rousse, Болгария, 7003
        • Mental Health Center - Rousse
      • Sofia, Болгария, 1680
        • Medical Center Intermedica, OOD
      • Sofia, Болгария, 1113
        • Medical Center St. Naum
      • Sofia, Болгария, 1784
        • MC 'Synexus Sofia' EOOD
      • Stara Zagora, Болгария, 6003
        • UMHAT Prof. Dr. St. Kirkovich AD
      • Stara Zagora, Болгария, 6000
        • MC 'Synexus Sofia' EOOD
      • Tzarev Brod, Болгария, 9747
        • State Psychiatric Hospital - Tzarev Brod
      • Varna, Болгария, 9020
        • Diagnostic Consulting Center Mladost - M Varna
      • Veliko Tarnovo, Болгария, 5000
        • Mental Health Center - Veliko Tarnovo EOOD
    • Nova Scotia
      • Sydney, Nova Scotia, Канада, B1P 1E1
        • A.K. Munshi Medical Inc.
    • Ontario
      • Toronto, Ontario, Канада, M3J 2C5
        • Canadian Phase Onward
    • Quebec
      • Montreal, Quebec, Канада, H1M 1B1
        • Clinique Force Medic (GCP Trials)
      • Jelgava, Латвия, LV-3008
        • The Mental Hospital of Jelgava Ģintermuiža - Psychiatry
      • Liepāja, Латвия, LV-3401
        • L. Keruze Practice in Psychiatry
      • Outpatient Centre of Psychiatry, Латвия, LV-4601
        • Hospital of Rezekne
      • Riga, Латвия, LV-1002
        • Riga Centre of Psychiatry and Narcology
      • Kaunas, Литва, 48259
        • Kaunas Silainiu Outpatient Clinic, Public Institution
      • Kaunas, Литва, 53136
        • Republic Kaunas Hospital
      • Kaunas, Литва, LT-44279
        • Romuvos Klinika, JSC
      • Kaunas, Литва, LT-50009
        • Hospital of Lithuanian University of Health Sciences Kaunas Clinics
      • Vilnius, Литва, 09112
        • Zirmunai Mental Health Center, Public Institution
      • Vilnius, Литва, 10309
        • Vilnius Mental Health Center
      • Vilnius, Литва, 10204
        • Antakalnis Psychiatric Consultation Centre, Public Institution
      • Šilutė, Литва, 99176
        • Medical Center Puriena JSC
      • Ipoh, Малайзия, 30990
        • Hospital Raja Permaisuri Bainun
      • Johor Bahru, Малайзия, 81200
        • Hospital Permai
      • Pulau Pinang, Малайзия, 10990
        • Hospital Pulau Pinang
      • Seremban, Малайзия, 70300
        • Hospital Tuanku Jaafar
      • Bełchatów, Польша, 97-400
        • Gabinet Lekarski Psychiatryczny Ireneusz Kaczorowski
      • Bialystok, Польша, 15-464
        • Wlokiennicza MED Specjalistyczna Praktyka Lekarska dr n.med. Tomasz Markowski
      • Bydgoszcz, Польша, 85-080
        • Przychodnia Srodmiescie SP. z o.o.
      • Gdansk, Польша, 80 546
        • Centrum Badan Klinicznych PI House sp z o o
      • Lodz, Польша, 90-009
        • Specjalistyczna Indywidualna Praktyka Lekarska
      • Lodz, Польша, 90-368
        • CCBR - Lodz - PL
      • Lublin, Польша, 20-582
        • Specjalistyczna Praktyka Lekarska Marek Domanski
      • Poznan, Польша, 60-702
        • Synexus Polska Sp. z.o.o. Oddzial w Poznaniu
      • Warsaw, Польша, 01 737
        • Specjalistyczny Osrodek Medycyny Wieku Dojrzalego Sp z o.o.
      • Warsaw, Польша, 02 957
        • Instytut Psychiatrii I Neurologii
      • Engel's, Россия, 413124
        • Engels psychiatric hospital
      • Kemerovo, Россия, 650036
        • Kemerovo Regional Clinical Psychiatric Hospital
      • Lipetsk Region, Россия, 399313
        • GUZ Lipetsk Regional psychoneurological Hospital #1
      • Moscow, Россия, 105082
        • JSC Scientific Centre of Personalized Medicine
      • Moscow, Россия, 107076
        • FSI Moscow SRI of Psychiatry of Minzdravsocrazvitia
      • Moscow, Россия, 107076
        • Moscow Scientific Research Institute of Psychiatry
      • Omsk, Россия, 644070
        • Clinical Psychiatry Hospital n.a. N.N. Solodovnikov
      • Saint Petersburg, Россия, 192019
        • St-Petersburg Bekhterev Psychoneurological Research Institute
      • Tomsk, Россия, 634009
        • Klinika StoLet Ltd
      • Yekaterinburg, Россия, 620030
        • Sverdlov Regional Psychiatric Clinical Hospital
      • Belgrade, Сербия, 11000
        • University Clinical Center of Serbia
      • Belgrade, Сербия, 11000
        • General Hospital Euromedik
      • Belgrade, Сербия, 11000
        • University Clinical Hospital Center Dr Dragisa Misovic- Dedi
      • Belgrade, Сербия, 11000
        • General Hospital Acibadem Bel Medic
      • Belgrade, Сербия, 11000
        • Institute of Mental Health Serbia
      • Kovin, Сербия, 26220
        • Special Neuropsychiatric Hospital Kovin
      • Kragujevac, Сербия, 34000
        • University Clinical Center Kragujevac
      • Niš, Сербия, 18000
        • Clinical Center Nis
      • Novi Kneževac, Сербия, 23330
        • Specialized Hospital for Neuropsychiatric Diseases Sveti Vracevi
      • Banská Bystrica, Словакия, 97401
        • Psychomed-Svatosavsky, s.r.o.
      • Bojnice, Словакия, 97201
        • Nemocnica s poliklinikou Prievidza so sidlom v Bojniciach
      • Košice, Словакия, 040 11
        • Epamed sro
      • Liptovský Mikuláš, Словакия, 03123
        • Liptovska Nemocnica S Poliklinikou Mudr. Ivana Stodolu
      • Rimavská Sobota, Словакия, 97901
        • Psychiatricka Ambulancia Psycholine S.R.O.
      • Trenčín, Словакия, 91101
        • FN Trencin
      • Trenčín, Словакия, 91108
        • Pro mente sana s.r.o.
      • Žilina, Словакия, 1207
        • Fakultna nemocnica s poliklinikou v Ziline
      • Derby, Соединенное Королевство, DE22 3LZ
        • Kingsway Hospital
      • Greater Manchester, Соединенное Королевство, M15 6SX
        • Synexus
      • Harrogate, Соединенное Королевство, HG1 2PW
        • Garden Valleys Resource Centre
      • London, Соединенное Королевство, SE5 8EF
        • Kings College Hospital NHS Trust
      • Redruth, Соединенное Королевство, TR15 2SP
        • Cornwall Partnership Foundation Trust
    • Alabama
      • Birmingham, Alabama, Соединенные Штаты, 35233
        • University of Alabama at Birmingham
    • Arizona
      • Tucson, Arizona, Соединенные Штаты, 85712
        • SW Biomedical Research LLC
    • California
      • Culver City, California, Соединенные Штаты, 90230
        • Proscience Research Group
      • Encino, California, Соединенные Штаты, 91316
        • Pharmacology Research Institute
      • Garden Grove, California, Соединенные Штаты, 92845
        • Collaborative NeuroScience Network
      • Long Beach, California, Соединенные Штаты, 90806
        • Collaborative NeuroScience Network
      • Los Alamitos, California, Соединенные Штаты, 90720
        • Pharmacology Research Institute
      • Los Angeles, California, Соединенные Штаты, 90025
        • CalNeuro Research
      • Newport Beach, California, Соединенные Штаты, 92660
        • Pharmacology Research Institute
      • Orange, California, Соединенные Штаты, 92868
        • NRC Research Institute
      • Orange, California, Соединенные Штаты, 92868
        • Pacific Neuropsychiatric Specialists
      • Pico Rivera, California, Соединенные Штаты, 90660
        • CNRI-Los Angeles, LLC
      • Rancho Cucamonga, California, Соединенные Штаты, 91730
        • Prospective Research Innovations Inc
      • Redlands, California, Соединенные Штаты, 92374
        • Anderson Clinical Research
      • San Diego, California, Соединенные Штаты, 92103
        • University of California at San Diego
      • Santa Ana, California, Соединенные Штаты, 92705
        • CI Trials
      • Santa Ana, California, Соединенные Штаты, 91704
        • National Research Institute
      • Santee, California, Соединенные Штаты, 92071
        • CMB Clinical Trials
      • Sherman Oaks, California, Соединенные Штаты, 91403
        • Schuster Medical Research Institute
      • Upland, California, Соединенные Штаты, 91786
        • Pacific Clinical Research Medical Group
    • Connecticut
      • Hartford, Connecticut, Соединенные Штаты, 06102
        • Hartford Hospital
    • Florida
      • Doral, Florida, Соединенные Штаты, 33166
        • Moonshine Research Center, Inc
      • Hallandale, Florida, Соединенные Штаты, 33009
        • Velocity Clinical Research, Hallandale Beach
      • Hialeah, Florida, Соединенные Штаты, 33012
        • Indago Research & Health Center Inc
      • Hialeah, Florida, Соединенные Штаты, 33012
        • New Life Medical Research Center, Inc.
      • Hialeah, Florida, Соединенные Штаты, 33013
        • Amedica Research Institute Inc
      • Lakeland, Florida, Соединенные Штаты, 33803
        • Meridien Research
      • Miami, Florida, Соединенные Штаты, 33122
        • Premier Clinical Research
      • Miami, Florida, Соединенные Штаты, 33125
        • Global Medical Institutes
      • Miami, Florida, Соединенные Штаты, 33137
        • Miami Jewish Health System
      • Orlando, Florida, Соединенные Штаты, 32806
        • Synexus Research Orlando
      • Orlando, Florida, Соединенные Штаты, 23801
        • Clinical Neuroscience Solutions
      • Tampa, Florida, Соединенные Штаты, 33612
        • University of South Florida
      • The Villages, Florida, Соединенные Штаты, 32162
        • Compass Research LLC-Bioclinica Research
    • Georgia
      • Atlanta, Georgia, Соединенные Штаты, 30331
        • Atlanta Center for Medical Research
      • Atlanta, Georgia, Соединенные Штаты, 30328
        • Synexus Clinical Research US Inc
      • Decatur, Georgia, Соединенные Штаты, 30030
        • iResearch Atlanta LLC
      • Marietta, Georgia, Соединенные Штаты, 30060
        • Psych Atlanta, P.C.
    • Illinois
      • Chicago, Illinois, Соединенные Штаты, 60634
        • Chicago Research Center
      • Libertyville, Illinois, Соединенные Штаты, 60048
        • Capstone Clinical Research
      • Lisle, Illinois, Соединенные Штаты, 60532
        • Alexian Brothers Health System
      • Naperville, Illinois, Соединенные Штаты, 60563
        • Baber Research Group
      • Oakbrook Terrace, Illinois, Соединенные Штаты, 60618
        • Lemah Creek Clinical Research
    • Kansas
      • Wichita, Kansas, Соединенные Штаты, 67214
        • Ascension via Christi Research
    • Louisiana
      • New Orleans, Louisiana, Соединенные Штаты, 70115
        • Riverstar Research
    • Maryland
      • Baltimore, Maryland, Соединенные Штаты, 21208
        • Pharmasite Research, Inc.
    • Massachusetts
      • New Bedford, Massachusetts, Соединенные Штаты, 02740
        • BTC of New Bedford
      • Roslindale, Massachusetts, Соединенные Штаты, 02135
        • Boston Clinical Trials & Medical Research
    • Missouri
      • O'Fallon, Missouri, Соединенные Штаты, 63368
        • Psychiatric Care and Research Center (PCRC)
    • New Jersey
      • Toms River, New Jersey, Соединенные Штаты, 08755
        • Bio Behavioral Health
    • New York
      • Brooklyn, New York, Соединенные Штаты, 11235
        • SPRI Clinical Trials, LLC
      • New York, New York, Соединенные Штаты, 10128
        • The Medical Research Network, LLC
      • New York, New York, Соединенные Штаты, 10017
        • Fieve Clinical Research Inc
      • Rochester, New York, Соединенные Штаты, 14618 1609
        • Finger Lakes Clinical Research
      • Staten Island, New York, Соединенные Штаты, 10312
        • Richmond Behavioral Associates
    • North Carolina
      • Durham, North Carolina, Соединенные Штаты, 27701
        • Velocity Clinical Research, Inc.
    • Ohio
      • Cincinnati, Ohio, Соединенные Штаты, 45219
        • University of Cincinnati, Dept of Psychiatry & Behavioral Neuroscience
      • Dayton, Ohio, Соединенные Штаты, 45417
        • Midwest Clinical Research Center
      • North Canton, Ohio, Соединенные Штаты, 44720
        • Neuro Behavioral Clinical Research
    • Oklahoma
      • Oklahoma City, Oklahoma, Соединенные Штаты, 73112
        • Sooner Clinical Research
      • Oklahoma City, Oklahoma, Соединенные Штаты, 73118
        • Paradigm Research Professionals, LLC
    • Pennsylvania
      • Pine Hill, Pennsylvania, Соединенные Штаты, 08021
        • Suburban Research Associates
      • Scranton, Pennsylvania, Соединенные Штаты, 18503
        • Global Medical Institutes
    • South Carolina
      • Mt. Pleasant, South Carolina, Соединенные Штаты, 29464
        • Coastal Carolina Research Center
    • Texas
      • Bellaire, Texas, Соединенные Штаты, 77401
        • West Houston Clinical Research Service
      • Fort Worth, Texas, Соединенные Штаты, 76104
        • North Texas Clinical Trials
      • Mansfield, Texas, Соединенные Штаты, 76054
        • Hawkins Psychiatry, PC
      • The Woodlands, Texas, Соединенные Штаты, 77381
        • Family Psychiatry of The Woodlands
      • Wichita Falls, Texas, Соединенные Штаты, 76309
        • Grayline Research Center
    • Utah
      • Clinton, Utah, Соединенные Штаты, 84015
        • Alpine Research Organization
      • Draper, Utah, Соединенные Штаты, 84020
        • Cedar Clinical Research
    • Virginia
      • Charlottesville, Virginia, Соединенные Штаты, 22903
        • University of Virginia
    • Washington
      • Bellevue, Washington, Соединенные Штаты, 98007
        • Northwest Clinical Research Center
      • Everett, Washington, Соединенные Штаты, 98201
        • Core Clinical Research
    • Wisconsin
      • Waukesha, Wisconsin, Соединенные Штаты, 53188
        • Cary J. Kohlenberg, MD, SC, dba, IPC Research.
      • Hlevakha, Украина, 8631
        • MNCE of Kyiv RC Regional Psychiatric and Narcological Medical Association
      • Kharkiv, Украина, 61068
        • Mnpe of Kharkiv Regional Council 'Regional Clinical Psychiatric Hospital #3'
      • Kyiv, Украина, 04080
        • Kyiv Territorial Medical Incorporation 'Psychiatry'
      • Kyiv, Украина, 1030
        • Railway Clinical Hospital #1 of Kiev Railway station of DTGO 'South-Western Railway'
      • Kyiv, Украина, 1034
        • Medical Center Health and Happy
      • Nove, Украина, 25491
        • Mnpe 'Regional Clinical Psychiatric Hospital of Kirovohrad Regional Council'
      • Ternopil, Украина, 46020
        • Ternopil RCCPH Depts of Psychiatry #2 (m) & Psychiatry #4 (f) Ternopil I.Ya. Gorbachevskyi SMU
      • Zaporizhzhya, Украина, 69600
        • Zaporizhzhia Regional Clinical Hospital
      • Brno, Чехия, 60200
        • Psychiatricka ambulance Saint Anne s.r.o.
      • Hradec Králové, Чехия, 500 09
        • NeuropsychiatrieHK, s.r.o.
      • Pilsen, Чехия, 301 00
        • A Shine S R O
      • Prague, Чехия, 100 00
        • Clintrial s r o
      • Prague, Чехия, 160 00
        • NeuropsychiatrieHK, s.r.o.
      • Prague, Чехия, 10000
        • AD71 s.r.o.
      • Prague, Чехия, 186 00
        • Institut Neuropsychiatricke pece

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

От 18 лет до 74 года (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria:

  • Meet diagnostic and statistical manual of mental disorders-5th edition (DSM-5) diagnostic criteria for major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the structured clinical interview for DSM-5 Axis I disorders-clinical trials version (SCID-CT) diagnosed with first depressive episode prior to age 60. The length of the current depressive episode must be less than or equal to (<=) 24 months
  • Have had an inadequate response to at least 1 but no more than 2 antidepressants, administered at an adequate dose and duration in the current episode of depression. The current antidepressant cannot be the first antidepressant treatment for the first lifetime episode of depression. An inadequate response is defined as less than (<) 50 percent (%) reduction but with some improvement (that is, improvement greater than [>] 0%) in depressive symptom severity with residual symptoms present other than insomnia, and overall good tolerability, as assessed by the Massachusetts General Hospital-Antidepressant Treatment Response Questionnaire (MGH-ATRQ)
  • Is receiving and tolerating well any one of the following selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) for depressive symptoms at screening, in any formulation and available in the participating country: citalopram, duloxetine, escitalopram, fluvoxamine, fluoxetine, milnacipran, levomilnacipran, paroxetine, sertraline, venlafaxine, desvenlafaxine, vilazodone, or vortioxetine at a stable dose (at or above therapeutic dose level) for at least 6 weeks, and for no greater than 18 months in the current episode
  • Have a hamilton depression rating scale (HDRS)-17 total score greater than or equal to (>=) 20 at the first screening interview, must not demonstrate a clinically significant improvement (that is, an improvement of > 20% on their HDRS-17 total score) from the first to the second independent HDRS-17 rating, and must have a HDRS-17 total score >18 at the second screening interview
  • Have a patient version insomnia severity index (ISI) total score >= 15 as well as a clinician version of the ISI total score >= 15 at the second screening visit
  • Body mass index (BMI) between 18 and 40 kilogram per meter square (kg/m^2), inclusive (BMI=weight/height^2)
  • Participant must be medically stable on the basis of the following: physical examination, vital signs (including blood pressure), and 12-lead electrocardiogram (ECG) performed at screening and baseline

Exclusion Criteria:

  • Has a recent (last 3 months) history of, or current signs and symptoms of, severe renal insufficiency (creatinine clearance [CrCl] less than [<] 30 milliliter per minute [mL/min]); clinically significant or unstable cardiovascular, respiratory, gastrointestinal, neurologic, hematologic, rheumatologic, immunologic or endocrine disorders. uncontrolled Type 1 or Type 2 diabetes mellitus
  • Has a history of treatment-resistant MDD, defined as a lack of response to 2 or more adequate antidepressant treatments in the current episode, as indicated by no or minimal (<25% improvement in symptoms) when treated with an antidepressant of adequate dose (per MGH-ATRQ) and duration (at least 6 weeks)
  • Has history or current diagnosis of a psychotic disorder, bipolar disorder, intellectual disability, autism spectrum disorder, borderline personality disorder, somatoform disorders
  • Has a history of moderate to severe substance use disorder including alcohol use disorder according to DSM-5 criteria within 6 months before screening
  • Has any significant primary sleep disorder, including but not limited to obstructive sleep apnea, restless leg syndrome, or parasomnias. Participants with insomnia disorder are allowed

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Двойной

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Экспериментальный: Seltorexant

Adult participants will receive seltorexant once daily from Day 1-7 and together with matching placebo from Day 8 till Day 182. Elderly participants will receive seltorexant once daily from Day 1-3 and together with matching placebo from Day 4 till Day 182.

Participants will receive seltorexant over-encapsulated tablet orally.

Participants will receive placebo over-encapsulated tablet matching to seltorexant orally.

Активный компаратор: Quetiapine Extended-Release (XR)

Adult participants will receive quetiapine XR once daily from Day 1-2, followed by an increase in dose from Day 3-7, and from Day 8-14 together with matching placebo. After Day 14, quetiapine XR twice daily from Day 14 till Day 182. Elderly participants will receive quetiapine XR once daily from Day 1-3 and twice from Day 4-7, followed by an increase in dose once daily from Day 8-14 together with matching placebo. After Day 14 till Day 182, quetiapine XR will be adjusted by investigator based on the participant's clinical response and tolerability.

Participants will receive quetiapine XR capsule orally.

Participants will receive placebo capsule matching to quetiapine XR orally.

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Percentage of Participants Who Achieved Response (Greater Than or Equal to [>=50] Percent Improvement in Montgomery-Asberg Depression Rating Scale [MADRS] Total Score From Baseline) at Week 26
Временное ограничение: Week 26

Percentage of participants who achieved response at Week 26 was reported. Responders were defined as participants with >= 50 percent (%) improvement in the MADRS total score from baseline. MADRS was a clinician-administered scale designed to measure depression severity and detected changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.

Week 26

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Change From Baseline to Week 26 in Weight
Временное ограничение: Baseline (Day 1) and Week 26

Change from baseline to Week 26 in weight was reported.

Baseline (Day 1) and Week 26
Time to Potentially Treatment Related Discontinuation of Study Drug
Временное ограничение: From first dose of study drug (Day 1) up to Week 30

Time to potentially treatment related discontinuation of study drug was reported. Time to discontinuation of study drug was defined as the number of days from the first dose of study drug to the last dose of study drug. Potentially treatment related discontinuation of study drug was defined as all study drug discontinuations excluding the potentially non-treatment related discontinuations (such as, loss of insurance for antidepressant therapy, movement/travel out of the area, change of work-schedule being unable to accommodate visit schedule, family circumstances, site terminated by sponsor, study terminated by sponsor). Kaplan-Meier estimate was used.

From first dose of study drug (Day 1) up to Week 30
Change From Baseline to Week 26 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Временное ограничение: Baseline (Day 1) and Week 26

Change from baseline to Week 26 in MADRS total score were reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.

Baseline (Day 1) and Week 26
Change From Baseline to Week 26 in MADRS-6 Total Score
Временное ограничение: Baseline (Day 1) and Week 26

Change from baseline to Week 26 in MADRS-6 total score was reported. The MADRS-6 scale was a clinician-administered questionnaire used to measure the severity of MDD symptoms. The MADRS-6 scale was a subset of the MADRS-10 scale, comprised of the following individual questionnaire items: apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), the overall score ranged from 0 to 36, higher scores represented a more severe condition.

Baseline (Day 1) and Week 26
Change From Baseline to Week 26 in the MADRS Without Sleep Item (MADRS-WOSI) Total Score
Временное ограничение: Baseline (Day 1) and Week 26

The MADRS was a clinician-rated scale designed to measure depression severity and detected changes due to antidepressant treatment. MADRS-WOSI was defined as the full MADRS without the sleep item. The MADRS-WOSI scale consisted of 9 items (apparent sadness, reported sadness, inner tension, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS-WOSI total score was the sum of scores from individual question items, which ranged from 0 to 54, higher scores represented a more severe condition. Negative change in MADRS total score indicated improvement.

Baseline (Day 1) and Week 26
Change From Baseline to Week 26 in Patient Health Questionnaire, 9-Item (PHQ-9) Total Score
Временное ограничение: Baseline (Day 1) and Week 26

Change from baseline to Week 26 in PHQ-9 total score was reported. The PHQ-9 is a 9-item, participant reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the diagnostic and statistical manual of mental disorders-5th edition (DSM-5) major depressive disorder (MDD) criteria. Each item was rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. Negative changes in PHQ-9 total score indicated improvement.

Baseline (Day 1) and Week 26
Percentage of Participants With MADRS Total Score Less Than or Equal to (<=) 12 at Week 26
Временное ограничение: Week 26

Percentage of participants with MADRS total score <=12 at Week 26 was reported. A participant was defined as a remitter at a given time point if the MADRS total score was <=12 at that time point. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.

Week 26
Percentage of Participants With a >=50 Percent Improvement in MADRS Total Score and MADRS <=18 at Week 26
Временное ограничение: Week 26

Percentage of participants with a >=50 percent improvement in MADRS total score and MADRS <=18 at Week 26 was reported. MADRS was a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluated the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item was scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms). MADRS total score was the sum of scores from individual question items, which ranged from 0 to 60, higher scores represented a more severe condition.

Week 26
Percentage of Participants With >=7 Percent Weight Increase From Baseline at Week 26
Временное ограничение: Week 26

Percentage of participants with >=7 percent weight increase from baseline at Week 26 was reported.

Week 26

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Следователи

  • Директор по исследованиям: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

15 сентября 2020 г.

Первичное завершение (Действительный)

3 октября 2023 г.

Завершение исследования (Действительный)

3 октября 2023 г.

Даты регистрации исследования

Первый отправленный

13 августа 2020 г.

Впервые представлено, что соответствует критериям контроля качества

13 августа 2020 г.

Первый опубликованный (Действительный)

14 августа 2020 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

13 ноября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

11 ноября 2026 г.

Последняя проверка

1 ноября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Другие идентификационные номера исследования

  • CR108810
  • 42847922MDD3005 (Другой идентификатор: Janssen Research & Development, LLC)
  • 2020-000341-14 (Номер EudraCT)

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

ДА

Описание плана IPD

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical- trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Да

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Нет

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться